- Home
- AOMR vs ACIU Comparison
AOMR vs ACIU Comparison
Compare AOMR & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AOMR
- ACIU
- Stock Information
- Founded
- AOMR 2018
- ACIU 2003
- Country
- AOMR United States
- ACIU Switzerland
- Employees
- AOMR N/A
- ACIU N/A
- Industry
- AOMR Real Estate Investment Trusts
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- AOMR Real Estate
- ACIU Health Care
- Exchange
- AOMR Nasdaq
- ACIU Nasdaq
- Market Cap
- AOMR 238.8M
- ACIU 213.3M
- IPO Year
- AOMR 2021
- ACIU 2016
- Fundamental
- Price
- AOMR $9.74
- ACIU $2.50
- Analyst Decision
- AOMR Strong Buy
- ACIU Strong Buy
- Analyst Count
- AOMR 6
- ACIU 2
- Target Price
- AOMR $11.25
- ACIU $10.00
- AVG Volume (30 Days)
- AOMR 203.7K
- ACIU 136.3K
- Earning Date
- AOMR 11-05-2025
- ACIU 11-04-2025
- Dividend Yield
- AOMR 13.10%
- ACIU N/A
- EPS Growth
- AOMR N/A
- ACIU N/A
- EPS
- AOMR 1.56
- ACIU N/A
- Revenue
- AOMR $57,661,000.00
- ACIU $36,362,036.00
- Revenue This Year
- AOMR N/A
- ACIU N/A
- Revenue Next Year
- AOMR $12.91
- ACIU $1,022.98
- P/E Ratio
- AOMR $6.25
- ACIU N/A
- Revenue Growth
- AOMR N/A
- ACIU 86.71
- 52 Week Low
- AOMR $7.36
- ACIU $1.43
- 52 Week High
- AOMR $10.88
- ACIU $3.98
- Technical
- Relative Strength Index (RSI)
- AOMR 50.88
- ACIU 62.56
- Support Level
- AOMR $9.61
- ACIU $2.35
- Resistance Level
- AOMR $9.88
- ACIU $2.59
- Average True Range (ATR)
- AOMR 0.20
- ACIU 0.15
- MACD
- AOMR -0.03
- ACIU 0.03
- Stochastic Oscillator
- AOMR 30.53
- ACIU 83.93
About AOMR Angel Oak Mortgage REIT Inc.
Angel Oak Mortgage REIT Inc is a real estate finance company focused on acquiring and investing in the first lien non-QM loans and other mortgage-related assets in the U.S. mortgage market. Its objective is to generate attractive risk-adjusted returns for its stockholders, through cash distributions and capital appreciation across interest rates and credit cycles.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.